In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.

摘要

ER-2 is a new investigational quinoline derivative with the formula 7a,13b-8,8-dimethylpyrrolo[2,3-d]pyrimidine-[2,1-a] pyrrolo[4,3:2,3]-7a,8,13,13b-tetrahydroquinoline 7 (compound 7), synthesized by Department of Organic Chemistry, University of Chennai, Chennai, India (Fig. 1). This drug has shown significant activity against gram-positive and gram-negative organisms (7). Mycoplasma pneumoniae is a significant cause of upper and lower respiratory tract infections in persons of all age groups (6, 8-10). In this study, we compared the in vitro antibacterial activity of ER-2 against a collection of mycoplasma species known to cause disease in humans to those of antimicrobial agents known to have in vitro activity against these organisms. Sixty-one M. pneumoniae isolates tested were collected from clinical specimens of persons with pneumonia. Forty M. hominis isolates were derived from clinical specimens from the urogenital tract. Ten of the isolates were resistant to tetracycline (MIC_(90), >=8 mug/ml).